The impact of immunopeptidomics: From basic research to clinical implementation.

Details

Ressource 1Download: 1-s2.0-S1044532323000180-main.pdf (1473.08 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_6B56B0492D5F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The impact of immunopeptidomics: From basic research to clinical implementation.
Journal
Seminars in immunology
Author(s)
Shapiro I.E., Bassani-Sternberg M.
ISSN
1096-3618 (Electronic)
ISSN-L
1044-5323
Publication state
Published
Issued date
03/2023
Peer-reviewed
Oui
Volume
66
Pages
101727
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The immunopeptidome is the set of peptides presented by the major histocompatibility complex (MHC) molecules, in humans also known as the human leukocyte antigen (HLA), on the surface of cells that mediate T-cell immunosurveillance. The immunopeptidome is a sampling of the cellular proteome and hence it contains information about the health state of cells. The peptide repertoire is influenced by intra- and extra-cellular perturbations - such as in the case of drug exposure, infection, or oncogenic transformation. Immunopeptidomics is the bioanalytical method by which the presented peptides are extracted from biological samples and analyzed by high-performance liquid chromatography coupled to tandem mass spectrometry (MS), resulting in a deep qualitative and quantitative snapshot of the immunopeptidome. In this review, we discuss published immunopeptidomics studies from recent years, grouped into three main domains: i) basic, ii) pre-clinical and iii) clinical research and applications. We review selected fundamental immunopeptidomics studies on the antigen processing and presentation machinery, on HLA restriction and studies that advanced our understanding of various diseases, and how exploration of the antigenic landscape allowed immune targeting at the pre-clinical stage, paving the way to pioneering exploratory clinical trials where immunopeptidomics is directly implemented in the conception of innovative treatments for cancer patients.
Keywords
Humans, Histocompatibility Antigens Class I, Histocompatibility Antigens Class II, HLA Antigens, Antigen Presentation, Peptides, Antigen Discovery, Clinical applications, Immunopeptidomics, Mass spectrometry
Pubmed
Web of science
Open Access
Yes
Create date
03/03/2023 15:22
Last modification date
29/03/2023 6:51
Usage data